It has been universally recognized that simply targeting systemic hyperglycemia and metabolic disorders is not sufficient to arrest the progression of DN,8, 40, 41, 42, 43 indicating that there must be other molecular mechanism responsible for therapeutic effects of IL-22 for DN. This evidence concerns the gene IL22 and Hyperglycemia.